Atherosclerosis in rheumatoid arthritis: Is it all about inflammation?

Nature Reviews Rheumatology

Volumn 11, Issue 7, 2015, Pages 390-400

  Skeoch, Sarah ^a   Bruce, Ian N ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CORTICOSTEROID DERIVATIVE; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MATRIX METALLOPROTEINASE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; ROSUVASTATIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DIABETES MELLITUS; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; RISK FACTOR;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 84933678127     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.40     Document Type: Review

References (119)

1. Maradit-Kremers, H., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402-411 (2005
2. Sololmon, D. H., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1608-1612 (2006
3. del Rincon, I., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737-2745 (2001
4. Hannawi, S., Haluska, B., Marwick, T. & Thomas, R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res. Ther. 9, R116 (2007
5. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045-2051 (2012
6. Rothwell, P. M., et al. Reanalysis of the final results of the european carotid surgery trial. Stroke 34, 514-523 (2003
7. Everett, B. M., et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199-207 (2013
8. Pasceri, V. & Yeh, E. T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100, 2124-2126 (1999
9. Anderson, T. J. Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 34, 631-638 (1999
10. Skaug, E. A., Madssen, E., Aspenes, S. T., Wisloff, U. & Ellingsen, O. Cardiovascular risk factors have larger impact on endothelial function in self-reported healthy women than men in the HUNT3 fitness study. PLoS ONE 9, e101371 (2014
11. Chia, S., et al. Intra-Arterial tumor necrosis factor α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arter. Thromb. Vasc. Biol. 23, 695-701 (2003
12. Legein, B., Temmerman, L., Biessen, E. & Lutgens, E. Inflammation and immune system interactions in atherosclerosis. Cell. Mol. Life Sci. 70, 3847-3869 (2013
13. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005
14. Sakakura, K., et al. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 22, 399-411 (2013
15. Sukhova, G. K., et al. Evidence for increased collagenolysis by interstitial collagenases 1 and 3 in vulnerable human atheromatous plaques. Circulation 99, 2503-2509 (1999
16. Sun, J., et al. Sustained acceleration in carotid atherosclerotic plaque progression with intraplaque hemorrhage: a long-Term time course study. JACC Cardiovasc. Imaging 5, 798-804 (2012
17. Redgrave, J. N. E., Lovett, J. K., Gallagher, P. J. & Rothwell, P. M. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms. Circulation 113, 2320-2328 (2006
18. Kaptoge, S., et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-Analysis. Eur. Heart J. 35, 578-589 (2014
19. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin 6 receptor pathways in coronary heart disease: a collaborative meta-Analysis of 82 studies. Lancet 379, 1205-1213 (2012
20. Kerwin, W. S., et al. Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241, 459-468 (2006
21. Davies, J. R., et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 36, 2642-2647 (2005
22. Sandoo, A., Veldhuijzen van Zanten, J. J. C. S., Metsios, G. S., Carroll, D. & Kitas, G. D. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 50, 2125-2139 (2011
23. Nagata-Sakurai, M., et al. Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum. 48, 3061-3067 (2003
24. Giles, J. T., et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 63, 3216-3225 (2011
25. Semb, A. G., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J. Rheumatol. 40, 359-368 (2013
26. Aubry, M. C., et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J. Rheumatol. 34, 937-942 (2007
27. van den Oever, I. A. M., et al. Rheumatoid arthritis is associated with systemic inflammation in coronary vessels [abstract]. Arthritis Rheum. 65 (Suppl. 10), 386 (2013
28. Karpouzas, G. A., et al. Prevalence, extent and composition of coronary plaque in patients with srheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann. Rheum. Dis. 73, 1797-1804 (2014
29. Goodson, N., Marks, J., Lunt, M. & Symmons, D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann. Rheum. Dis. 64, 1595-1601 (2005
30. Gabriel, S. E., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48, 54-58 (2003
31. Barton, A. & Worthington, J. Genetic susceptibility to rheumatoid arthritis: an emerging picture. Arthritis Care Res. 61, 1441-1446 (2009
32. Roberts, R. & Stewart, A. F. R. Genes and coronary artery disease: where are we? J. Am. Coll. Cardiol. 60, 1715-1721 (2012
33. Stahl, E. A., et al. Genome-wide association study meta-Analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508-514 (2010
34. Farrall, M., et al Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet. 2, e72 (2006
35. Torkamani, A., Topol, E. J. & Schork, N. J. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 92, 265-272 (2008
36. Karczewski, K. J., et al. Systematic functional regulatory assessment of disease-Associated variants. Proc. Natl Acad. Sci. USA 110, 9607-9612 (2013
37. Bowes, J. & Barton, A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 47, 399-402 (2008
38. Paakkanen, R., et al. Proinflammatory HLA-DRB1 01-haplotype predisposes to ST elevation myocardial infarction. Atherosclerosis 221, 461-466 (2012
39. Shimane, K., et al. A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann. Rheum. Dis. 68, 377-383 (2009
40. Fries, J. F., et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum. 46, 2320-2329 (2002
41. Swanberg, M., et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat. Genet. 37, 486-494 (2005
42. Nolan, D., et al. Genome-wide linkage analysis of cardiovascular disease biomarkers in a large, multigenerational family. PLoS ONE 8, e71779 (2013
43. Sarwar, N., et al. Interleukin 6 receptor pathways in coronary heart disease: a collaborative meta-Analysis of 82 studies. Lancet 379, 1205-1213 (2012
44. Ikonomidis, I., Lekakis, J., Vamvakou, G., Andreotti, F. & Nihoyannopoulos, P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am. Heart J. 149, 832-839 (2005
45. Chen, Y., Dawes, P. T., Packham, J. C. & Mattey, D. L. Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J. Rheumatol. 38, 802-809 (2011
46. Lahiri, M., et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register (the EPIC 2 NOAR Study). Ann. Rheum. Dis. 73, 219-226 (2014
47. Mikuls, T. R., et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 66, 1090-1100 (2014
48. Mikuls, T. R., et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 64, 3522-3530 (2012
49. Bahekar, A. A., Singh, S., Saha, S., Molnar, J. & Arora, R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-Analysis. Am. Heart J. 154, 830-837 (2007
50. Edwards, C. J., et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 93, 1263-1267 (2007
51. Cambridge, G., Acharya, J., Cooper, J. A., Edwards, J. C. & Humphries, S. E. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 228, 243-246 (2013
52. Gonzalez, A., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann. Rheum. Dis. 67, 64-69 (2008
53. Arts, E. E. A., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 74, 668-674 (2015
54. Boyer, J. F., Gourraud, P. A., Cantagrel, A., Davignon, J. L. & Constantin, A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-Analysis. Joint Bone Spine 78, 179-183 (2011
55. Montagna, G. L., et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabet. Vasc. Dis. Res. 4, 130-135 (2007
56. Mirjafari, H., et al. Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Res. Ther. 13, R159 (2011
57. Dessein, P. H., Joffe, B. I. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 54, 2765-2775 (2006
58. Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N. & Drosos, A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765-766 (2005
59. Stavropoulos-Kalinoglou, A., et al. Anti-Tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012
60. Popa, C., et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J. Rheumatol. 36, 724-730 (2009
61. Derdemezis, C. S., et al. Effects of a 6 month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam. Clin. Pharmacol. 23, 595-600 (2009
62. Targonska-Stepniak, B., Dryglewska, M. & Majdan, M. Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatol. Int. 30, 731-737 (2010
63. Santos, M. J., Vinagre, F., Canas da Silva, J., Gil, V. & Fonseca, J. E. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin. Exp. Rheumatol. 29, 470-476 (2011
64. Giles, J. T., et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 62, 3173-3182 (2010
65. Kremers, H. M., Nicola, P. J., Crowson, C. S., Ballman, K. V. & Gabriel, S. E. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 50, 3450-3457 (2004
66. Zhang, J., et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-Analysis of observational studies. PLoS ONE 8, e78151 (2013
67. Toms, T. E., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-Associated cardiovascular risk? Ann. Rheum. Dis. 69, 683-688 (2010
68. Hahn, B. H., Grossman, J., Chen, W. & McMahon, M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J. Autoimmun. 28, 69-75 (2007
69. Georgiadis, A., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-A prospective, controlled study. Arthritis Res. Ther. 8, R82 (2006
70. McMahon, M., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 2541-2549 (2006
71. Charles-Schoeman, C., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 71, 1157-1162 (2012
72. Myasoedova, E., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482-487 (2011
73. Robertson, J., Peters, M. J., McInnes, I. B. & Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513-523 (2013
74. Navarro-Millan, I., et al. Changes in lipoproteins associated with methotrexate therapy or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 65, 1430-1438 (2013
75. Papadopoulos, N. G., et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin. Exp. Rheumatol. 23, 861-866 (2014
76. Hyrich, K. L., Watson, K. D., Silman, A. J. & Symmons, D. P. M. Predictors of response to anti-TNFα therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45, 1558-1565 (2006
77. Panoulas, V. F., et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47, 1286-1298 (2008
78. Mattey, D. L., et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum. 56, 1408-1416 (2007
79. Farragher, T. M., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 58, 359-369 (2008
80. Gorman, J. D., et al. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-Analysis of 3, 240 rheumatoid arthritis patients. Arthritis Rheum. 50, 400-412 (2004
81. Thomson, W., et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum. 42, 757-762 (1999
82. Weyand, C. M., Xie, C. & Goronzy, J. J. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J. Clin. Invest. 89, 2033-2039 (1992
83. Farragher, T. M., et al. Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care Res. 62, 676-682 (2010
84. Rodriguez-Rodriguez, L., et al. Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm. 2012, 574817 (2012
85. Wolfe, F., et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481-494 (1994
86. Naz, S. M., Farragher, T. M., Bunn, D. K., Symmons, D. P. & Bruce, I. N. The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum. 58, 985-989 (2008
87. Turesson, C., McClelland, R. L., Christianson, T. J. H. & Matteson, E. L. Severe extra-Articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 70-75 (2007
88. Jacobsson, L. T. H., et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 44, 1170-1176 (2001
89. Wallberg-Jonsson, S., Johansson, H., Ohman, M. L. & Rantapaa-Dahlqvist, S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J. Rheumatol. 26, 2562-2571 (1999
90. Goodson, N. J., et al. Baseline levels of C reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 52, 2293-2299 (2005
91. Rose, S. et. al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis and healthy subjects by FDG-PET/CT: a pilot study. Am. J. Cardiovasc. Dis. 3, 273-278 (2013
92. Mäki-Petäjä, K. M., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-Tumor necrosis factor-α therapy. Circulation 114, 1185-1192 (2006
93. Tahara, N., et al. Vascular inflammation evaluated by 18F fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J. Am. Coll. Cardiol. 49, 1533-1539 (2007
94. Rominger, A., et al. 18F FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J. Nuclear Med. 50, 1611-1620 (2009
95. Protogerou, A., et al. Arterial hypertension assessed out of office in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-Associated white coat phenomenon. Arthritis Res. Ther. 15, R142 (2013
96. Peters, M. J., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325-331 (2010
97. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100 (Suppl. 2), ii1-ii67 (2014
98. ATACC RA Consortium. A TransAtlantic Cardiovascular risk Calculator for Rheumatoid Arthritis [online], http://atacc-ra.com/(2015
99. Myasoedova, E., Gabriel, S. E., Green, A. B., Matteson, E. L. & Crowson, C. S. Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study. Arthritis Care Res. 65, 1592-1599 (2013
100. Semb, A. G., Holme, I., Kvien, T. K. & Pedersen, T. R. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 50, 324-329 (2011
101. Semb, A. G., et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 64, 2836-2846 (2012
102. Ridker, P. M., et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008
103. Tahara, N., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48, 1825-1831 (2006
104. Dadoun, S., et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-Analysis. Joint Bone Spine 80, 29-33 (2013
105. Brown, A. K., et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 54, 3761-3773 (2006
106. Ridker, P. M., Rifai, N., Rose, L., Buring, J. E. & Cook, N. R. Comparison of C reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002
107. Micha, R., et al. Systematic review and meta-Analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108, 1362-1370 (2011
108. Westlake, S. L., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49, 295-307 (2010
109. Avina-Zubieta, J. A., et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 52, 68-75 (2013
110. del Rincon, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M. & Escalante, A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 66, 264-272 (2014
111. Sihvonen, S., et al. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J. Rheumatol. 33, 1740-1746 (2006
112. Davis, J. M., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 56, 820-830 (2007
113. Barnabe, C., Martin, B. J. & Ghali, W. A. Systematic review and meta-Analysis: anti-Tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 63, 522-529 (2011
114. Westlake, S. L., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 50, 518-531 (2011
115. Hyrich, K. L., Watson, K. D., Lunt, M. & Symmons, D. P. M. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 50, 117-23 (2011
116. Lunt, M., Watson, K. D., Dixon, W. G., Symmons, D. P. & Hyrich, K. L. No evidence of association between anti-Tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 62, 3145-3153 (2010
117. Low, A., et al. Comparison of the occurrence and severity of myocardial infarction in subjects with rheumatoid arthritis receiving tumour necrosis factor inhibitors or standard non-biologic disease modifying antirheumatic drugs: results from a linkage between the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. Rheumatology (Oxford) 53 (Suppl. 1), i34-i35 (2014
118. van Vollenhoven, R. F., et al. Long-Term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 72, 1496-1502 (2013
119. Listing, J., et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF α inhibitors and rituximab. Ann. Rheum. Dis. 74, 415-421 (2015